124 related articles for article (PubMed ID: 7919460)
1. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
[TBL] [Abstract][Full Text] [Related]
2. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Lee JH; Naito M; Tsuruo T
Cancer Res; 1994 May; 54(9):2398-403. PubMed ID: 8162587
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
4. 7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Rohde D; Raffenberg G; Kaviani S; Wolff J; Jakse G
Urol Res; 1998; 26(4):243-7. PubMed ID: 9759997
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
6. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
7. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
8. Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149.
Ishida T; Nishio K; Kurokawa H; Arioka H; Fukumoto H; Fukuoka K; Nomoto T; Yokote H; Hasegawa S; Saijo N
Int J Cancer; 1997 Sep; 72(5):865-70. PubMed ID: 9311606
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
10. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation.
McAdam SR; Knox RJ; Hartley JA; Masters JR
Biochem Pharmacol; 1998 Jun; 55(11):1777-83. PubMed ID: 9714295
[TBL] [Abstract][Full Text] [Related]
11. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells.
Pan SS; Yu F; Hipsher C
Mol Pharmacol; 1993 Jun; 43(6):870-7. PubMed ID: 8316219
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on the action of 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C and of mitomycin C on cultured HL-60 cells and isolated phage and plasmid DNA.
Ishioka C; Kanamaru R; Konishi Y; Ishikawa A; Shibata H; Wakui A
Cancer Chemother Pharmacol; 1990; 26(2):117-21. PubMed ID: 2112051
[TBL] [Abstract][Full Text] [Related]
14. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines.
Lambert PA; Kang Y; Greaves B; Perry RR
J Surg Res; 1998 Dec; 80(2):177-81. PubMed ID: 9878310
[TBL] [Abstract][Full Text] [Related]
15. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.
Pan SS; Akman SA; Forrest GL; Hipsher C; Johnson R
Cancer Chemother Pharmacol; 1992; 31(1):23-31. PubMed ID: 1458556
[TBL] [Abstract][Full Text] [Related]
16. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells.
Willson JK; Long BH; Chakrabarty S; Brattain DE; Brattain MG
Cancer Res; 1985 Nov; 45(11 Pt 1):5281-6. PubMed ID: 3931904
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Singh SV; Xu BH; Gupta V; Emerson EO; Zaren HA; Jani JP
Cancer Lett; 1995 Aug; 95(1-2):49-56. PubMed ID: 7656243
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282.
Chakrabarty S; Danels YJ; Long BH; Willson JK; Brattain MG
Cancer Res; 1986 Jul; 46(7):3456-8. PubMed ID: 3754788
[TBL] [Abstract][Full Text] [Related]
19. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Takahashi K; Yokoyama M; Takahashi H; Wakui A
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
[TBL] [Abstract][Full Text] [Related]
20. Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
Ashizawa T; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Apr; 4(2):181-8. PubMed ID: 8490196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
